In his weekly clinical update Dr. Griffin discusses Dr. Griffin discusses progress toward poliomyelitis eradication in Afghanistan, reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons, reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters, authorized updated (Bivalent) COVID-19 vaccines for children down to 6 months of age, low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster, efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB, incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir, and the effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Progress toward Poliomyelitis eradication in Afghanistan (CDC) Reduced risk for Mpox after receipt of 1 or 2 Doses of JYNNEOS vaccine (CDC) Reduced airborne transmission of BA.1 Omicron virus in Syrian hamsters (PLOS) Authorized bivalent vaccines for children down to 6 months of age (FDA) Low neutralization of BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine (Nature) Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB (NEJM) Viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir (JAMA) Paxlovid patient eligbiliity screening checklist (FDA) Effectiveness of COVID-19 vaccines in prevention of post–infection conditions (ASHE) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 964 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]